Experiences with Medications for Addiction Treatment Among Emergency Department Patients with Opioid Use Disorder

• Published in: The western journal of emergency medicine 2023-02, Vol.24 (2), p.236-242
• Main Authors: Goldfine, Charlotte E, Chapman, Brittany P, Taylor, Melissa M, Bradley, Evan S, Carreiro, Stephanie P, Rosen, Rochelle K, Babu, Kavita M, Lai, Jeffrey T
• Format: Article
• Language: English
• Subjects: Adult; Analgesics, Opioid - therapeutic use; Behavioral Health; Buprenorphine - therapeutic use; Drug withdrawal; Emergency medical care; Emergency Service, Hospital; Humans; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders - drug therapy; Substance abuse treatment; Substance use disorder; Substance Withdrawal Syndrome - drug therapy
• ISSN: 1936-900X; 1936-9018; 1936-9018
• DOI: 10.5811/westjem.2022.9.57821

Medications for addiction treatment (MAT) are the evidence-based standard of care for treatment of opioid use disorder (OUD), but stigma continues to surround their use. We conducted an exploratory study to characterize perceptions of different types of MAT among people who use drugs. We conducted this qualitative study in adults with a history of non-medical opioid use who presented to an emergency department for complications of OUD. A semi-structured interview that explored knowledge, perceptions, and attitudes toward MAT was administered, and applied thematic analysis conducted. We enrolled 20 adults. All participants had prior experience with MAT. Among participants indicating a preferred treatment modality, buprenorphine was the commonly favored agent. Previous experience with prolonged withdrawal symptoms upon MAT discontinuation and the perception of "trading one drug for another" were common reasons for reluctance to engage in agonist or partial-agonist therapy. While some participants preferred treatment with naltrexone, others were unwilling to initiate antagonist therapy due to fear of precipitated withdrawal. Most participants strongly considered the aversive nature of MAT discontinuation as a barrier to initiating treatment. Participants overall viewed MAT positively, but many had strong preferences for a particular agent. The anticipation of withdrawal symptoms during initiation and cessation of treatment affected willingness to engage in a specific therapy. Future educational materials for people who use drugs may focus on comparisons of respective benefits and drawbacks of agonists, partial agonists, and antagonists. Emergency clinicians must be prepared to answer questions about MAT discontinuation to effectively engage patients with OUD.